Abstract

Viruses are intracellular obligate parasites and the host cellular machinery is usually recruited for their replication. Human eukaryotic translation initiation factor 3 (eIF3) could be directly recruited by the hepatitis C virus (HCV) internal ribosome entry site (IRES) to promote the translation of viral proteins. In this study, we establish a fluorescence polarization (FP) based high throughput screening (HTS) system targeting the interaction between HCV IRES and eIF3. By screening a total of 894 compounds with this HTS system, two compounds (Mucl39526 and NP39) are found to disturb the interaction between HCV IRES and eIF3. And these two compounds are further demonstrated to inhibit the HCV IRES-dependent translation in vitro. Thus, this HTS system is functional to screen the potential HCV replication inhibitors targeting human eIF3, which is helpful to overcome the problem of viral resistance. Surprisingly, one compound HP-3, a kind of oxytocin antagonist, is discovered to significantly enhance the interaction between HCV IRES and eIF3 by this HTS system. HP-3 is demonstrated to directly interact with HCV IRES and promote the HCV IRES-dependent translation both in vitro and in vivo, which strongly suggests that HP-3 has potentials to promote HCV replication. Therefore, this HTS system is also useful to screen the potential HCV replication enhancers, which is meaningful for understanding the viral replication and screening novel antiviral drugs. To our knowledge, this is the first HTS system targeting the interaction between eIF3 and HCV IRES, which could be applied to screen both potential HCV replication inhibitors and enhancers.

Highlights

  • Hepatitis C virus (HCV) infection is a major cause of clinical burden worldwide because many patients can develop complications including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (Sun et al, 2010)

  • This is the first high throughput screening (HTS) system targeting the interaction between eukaryotic translation initiation factor 3 (eIF3) and hepatitis C virus (HCV) internal ribosome entry site (IRES), which could be applied to screen both potential HCV replication enhancers and inhibitors in the future

  • The initial purpose of this study is to establish an effective HTS system and screen the potential HCV replication inhibitors targeting the interaction between HCV IRES and eIF3

Read more

Summary

Introduction

Hepatitis C virus (HCV) infection is a major cause of clinical burden worldwide because many patients can develop complications including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (Sun et al, 2010). The translation of the viral genomic RNA is driven by HCV IRES, which can help the virus to evade the host immune response by suppressing canonical cap-dependent translation (Fraser and Doudna, 2007). Sofosbuvir is proposed to be one most effective anti-HCV drug, resistant variants to sofosbuvir were found at different frequencies in worldwide HCV-1b sequences, and the high frequency of double mutation L159F-C316N observed in Brazilian HCV-1b patients (Peresda-Silva et al, 2017). Targeting a host factor rather than a viral protein might avoid the drug resistance for the virus (Sun et al, 2010). Development of new classes of antiviral compounds targeting host factors is always needed

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call